NanoViricides Files Measles Drug for Rare Disease Status
SHELTON, Connecticut, United States, April 7, 2026 NanoViricides, Inc., a clinical-stage biopharmaceutical company, announced that it has filed an...
Rare Pediatric Disease
Advertisement
OS Therapies Advances OST-HER2 Toward FDA Approval
NEW YORK, March 31, 2026 — OS Therapies, Inc a clinical-stage oncology company specializing in listeria-based cancer immunotherapies, has...
Immusoft Earns FDA Rare Pediatric Disease Status for ISP-002
SAN FRANCISCO, CALIFORNIA | January 26, 2026 — Immusoft, a clinical-stage biotechnology company pioneering engineered B cell therapies, announced...
FDA Reviews New Data to Advance SL1009 for Rare PDCD
ROSWELL, Ga., DUBLIN & HAMILTON, Bermuda — December 9, 2025 — Saol Therapeutics announced that the U.S. Food and...
FDA Issues Complete Response Letter for SL1009 in PDCD Treatment
ROSWELL, Ga., September 8, 2025 — Saol Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has...
Advertisement
